HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
-
REGULATORY LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
-
BUSINESS Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
-
BUSINESS Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
-
REGULATORY LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
-
BUSINESS Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
-
REGULATORY Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
-
BUSINESS Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
-
BUSINESS Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
-
REGULATORY Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
-
ACADEMIA Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
-
REGULATORY Japan Approves Mefeego as First Abortion Pill
May 1, 2023
-
REGULATORY Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
-
BUSINESS 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
-
ACADEMIA More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
-
BUSINESS Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
-
BUSINESS Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
April 25, 2023
-
REGULATORY Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
-
BUSINESS Drug Makers’ New Grad Hiring in Japan Up 5.8%, Rising for 1st Time since FY2020
April 21, 2023
-
BUSINESS Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
April 21, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
